WO2010032986A2 - Nouveaux dérivés de 5-(4-aminophenyl)-isoquinoline, leurs sels pharmaceutiquement acceptables, procédé de production associé et composition contenant les dérivés comme principe actif pour la prophylaxie et le traitement d'états pathologiques induits par l'hyperactivité de la kinase raf - Google Patents
Nouveaux dérivés de 5-(4-aminophenyl)-isoquinoline, leurs sels pharmaceutiquement acceptables, procédé de production associé et composition contenant les dérivés comme principe actif pour la prophylaxie et le traitement d'états pathologiques induits par l'hyperactivité de la kinase raf Download PDFInfo
- Publication number
- WO2010032986A2 WO2010032986A2 PCT/KR2009/005326 KR2009005326W WO2010032986A2 WO 2010032986 A2 WO2010032986 A2 WO 2010032986A2 KR 2009005326 W KR2009005326 W KR 2009005326W WO 2010032986 A2 WO2010032986 A2 WO 2010032986A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- formula
- compound
- trifluoromethyl
- isoquinolin
- Prior art date
Links
- 0 CC(C)(C)OC(Nc(cc1)ccc1-c1cccc2c*([O-])ccc12)=O Chemical compound CC(C)(C)OC(Nc(cc1)ccc1-c1cccc2c*([O-])ccc12)=O 0.000 description 1
- HSJNIOYPTSKQBD-UHFFFAOYSA-N CC(C)(C)OC(Nc1ccc(B2OC(C)(C)C(C)(C)O2)cc1)=O Chemical compound CC(C)(C)OC(Nc1ccc(B2OC(C)(C)C(C)(C)O2)cc1)=O HSJNIOYPTSKQBD-UHFFFAOYSA-N 0.000 description 1
- JWNCTIHWUUIHEB-UHFFFAOYSA-N CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2NC(Nc(cc2)cc(C)c2-c2cccc3c2ccnc3N)=O)CC1 Chemical compound CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2NC(Nc(cc2)cc(C)c2-c2cccc3c2ccnc3N)=O)CC1 JWNCTIHWUUIHEB-UHFFFAOYSA-N 0.000 description 1
- OSDWWMAFQMEYSA-UHFFFAOYSA-N CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2NC(Nc(cc2)ccc2-c2cccc3c(C(N)=O)nccc23)=O)CC1 Chemical compound CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2NC(Nc(cc2)ccc2-c2cccc3c(C(N)=O)nccc23)=O)CC1 OSDWWMAFQMEYSA-UHFFFAOYSA-N 0.000 description 1
- XGHPIXOBBHBWKD-UHFFFAOYSA-N CN(CC1)CCN1c1cc(C(Nc(cc2)ccc2-c2c(ccnc3)c3ccc2)=O)cc(C(F)(F)F)c1 Chemical compound CN(CC1)CCN1c1cc(C(Nc(cc2)ccc2-c2c(ccnc3)c3ccc2)=O)cc(C(F)(F)F)c1 XGHPIXOBBHBWKD-UHFFFAOYSA-N 0.000 description 1
- SFNWLRIWMRLAOS-UHFFFAOYSA-N Cc(nc1)c[n]1-c1cc(C(Nc(cc2)ccc2-c2c(ccnc3)c3ccc2)=O)cc(C(F)(F)F)c1 Chemical compound Cc(nc1)c[n]1-c1cc(C(Nc(cc2)ccc2-c2c(ccnc3)c3ccc2)=O)cc(C(F)(F)F)c1 SFNWLRIWMRLAOS-UHFFFAOYSA-N 0.000 description 1
- LPUWWBUPDBFCSO-UHFFFAOYSA-N O=C(Nc(cc1)ccc1-c1c(ccnc2Cl)c2ccc1)OCc1ccccc1 Chemical compound O=C(Nc(cc1)ccc1-c1c(ccnc2Cl)c2ccc1)OCc1ccccc1 LPUWWBUPDBFCSO-UHFFFAOYSA-N 0.000 description 1
- KVWLOLDSFXNBSS-UHFFFAOYSA-N O=C(c(cc1)cc(C(F)(F)F)c1N1CCOCC1)Nc(cc1)ccc1-c1c(ccnc2)c2ccc1 Chemical compound O=C(c(cc1)cc(C(F)(F)F)c1N1CCOCC1)Nc(cc1)ccc1-c1c(ccnc2)c2ccc1 KVWLOLDSFXNBSS-UHFFFAOYSA-N 0.000 description 1
- WOKTVNPETOINAP-UHFFFAOYSA-N OC(CC1)CCN1c1cc(C(Nc(cc2)ccc2-c2c(ccnc3)c3ccc2)=O)cc(C(F)(F)F)c1 Chemical compound OC(CC1)CCN1c1cc(C(Nc(cc2)ccc2-c2c(ccnc3)c3ccc2)=O)cc(C(F)(F)F)c1 WOKTVNPETOINAP-UHFFFAOYSA-N 0.000 description 1
- NQVFXQBKVSLJID-UHFFFAOYSA-N [O-][N+](c1nccc2c1cccc2Br)=O Chemical compound [O-][N+](c1nccc2c1cccc2Br)=O NQVFXQBKVSLJID-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
Abstract
L'invention concerne un nouveau dérivé de 5-(4-aminophényl)-isoquinoline ou un de ses sels pharmaceutiquement acceptable, un procédé de production associé, et une composition contenant ledit dérivé en tant que principe actif utilisé dans la prophylaxie et le traitement d'états pathologiques induits par l'hyperactivité des kinases Raf. La composition contenant le dérivé de 5-(4-aminophenyl)-isoquinoline de l'invention inhibe efficacement l'activité des kinases Raf et particulièrement la kinase B-raf, et le dérivé peut être ainsi utilisé avec un effet positif dans la prophylaxie et le traitement de cancers ou de mélanomes induits par l'hyperactivité des kinases Raf.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080091405A KR20100032496A (ko) | 2008-09-18 | 2008-09-18 | 신규 5-(4-아미노페닐)-이소퀴놀린 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 Raf 키나제의 과활성에 의해 유발되는 질환의 예방 또는 치료용 조성물 |
KR10-2008-0091405 | 2008-09-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010032986A2 true WO2010032986A2 (fr) | 2010-03-25 |
WO2010032986A3 WO2010032986A3 (fr) | 2010-08-19 |
Family
ID=42040023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/005326 WO2010032986A2 (fr) | 2008-09-18 | 2009-09-18 | Nouveaux dérivés de 5-(4-aminophenyl)-isoquinoline, leurs sels pharmaceutiquement acceptables, procédé de production associé et composition contenant les dérivés comme principe actif pour la prophylaxie et le traitement d'états pathologiques induits par l'hyperactivité de la kinase raf |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20100032496A (fr) |
WO (1) | WO2010032986A2 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
WO2018146253A1 (fr) | 2017-02-10 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions pharmaceutiques pour le traitement de cancers associés à l'activation de la voie mapk |
WO2019133810A1 (fr) | 2017-12-28 | 2019-07-04 | Tract Pharmaceuticals, Inc. | Systèmes de culture de cellules souches pour cellules souches épithéliales colonnaires, et leurs utilisations |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102337870B1 (ko) * | 2020-02-03 | 2021-12-10 | 순천대학교 산학협력단 | 세포자멸사를 유도하는 치환된 다이아릴우레아 화합물 및 이를 포함하는 항암용 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030114679A1 (en) * | 2001-09-12 | 2003-06-19 | Mceachern Ernest J. | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings |
WO2005049576A1 (fr) * | 2003-11-19 | 2005-06-02 | Glaxo Group Limited | Isoquinolines substituees utiles pour le traitement de maladies du type cancer et atherosclerose |
WO2005049574A1 (fr) * | 2003-11-20 | 2005-06-02 | Warner-Lambert Company Llc | Modulateurs du recepteur androgene |
KR20070009530A (ko) * | 2003-09-24 | 2007-01-18 | 노파르티스 아게 | 증식성 질환 치료에 유용한 raf-키나아제 억제제로서의1,4-이치환된 이소퀴놀린 유도체 |
US20070037796A1 (en) * | 2003-11-25 | 2007-02-15 | Barda David A | 7-Phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b) |
-
2008
- 2008-09-18 KR KR1020080091405A patent/KR20100032496A/ko not_active Application Discontinuation
-
2009
- 2009-09-18 WO PCT/KR2009/005326 patent/WO2010032986A2/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030114679A1 (en) * | 2001-09-12 | 2003-06-19 | Mceachern Ernest J. | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings |
KR20070009530A (ko) * | 2003-09-24 | 2007-01-18 | 노파르티스 아게 | 증식성 질환 치료에 유용한 raf-키나아제 억제제로서의1,4-이치환된 이소퀴놀린 유도체 |
WO2005049576A1 (fr) * | 2003-11-19 | 2005-06-02 | Glaxo Group Limited | Isoquinolines substituees utiles pour le traitement de maladies du type cancer et atherosclerose |
WO2005049574A1 (fr) * | 2003-11-20 | 2005-06-02 | Warner-Lambert Company Llc | Modulateurs du recepteur androgene |
US20070037796A1 (en) * | 2003-11-25 | 2007-02-15 | Barda David A | 7-Phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
WO2018146253A1 (fr) | 2017-02-10 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions pharmaceutiques pour le traitement de cancers associés à l'activation de la voie mapk |
WO2019133810A1 (fr) | 2017-12-28 | 2019-07-04 | Tract Pharmaceuticals, Inc. | Systèmes de culture de cellules souches pour cellules souches épithéliales colonnaires, et leurs utilisations |
Also Published As
Publication number | Publication date |
---|---|
WO2010032986A3 (fr) | 2010-08-19 |
KR20100032496A (ko) | 2010-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017204445A2 (fr) | Composition pharmaceutique induisant la décomposition de la protéine alk, et composition pharmaceutique pour la prévention ou le traitement du cancer la contenant en tant que composant actif | |
WO2010064875A2 (fr) | Nouveaux dérivés d'indazole ou sels pharmaceutiquement acceptables de ceux-ci en tant qu'inhibiteurs de protéine kinase pour le traitement de maladies prolifératives, et composition pharmaceutique contenant ceux-ci en tant que substance active | |
WO2019190259A1 (fr) | Nouveau dérivé de sulfonamide ayant un effet inhibiteur sur la mutation du récepteur du facteur de croissance épidermique | |
WO2016032120A1 (fr) | Nouveau dérivé d'amino-phényl-sulfonyl-acétate et son utilisation | |
WO2017142325A1 (fr) | Nouveau composé thiophène substitué en 2,3,5 utilisé en tant qu'inhibiteur de la protéine kinase | |
WO2018139903A1 (fr) | Composé pyrimidine et son utilisation pharmaceutique | |
WO2014109530A1 (fr) | Dérivé 2-(phényléthynyl)thiéno[3,4-b]pyrazine, et composition pharmaceutique comprenant ce dérivé et destinée à la prévention ou au traitement du cancer | |
WO2019231271A1 (fr) | Dérivés hétérocycliques et leur utilisation | |
WO2010032986A2 (fr) | Nouveaux dérivés de 5-(4-aminophenyl)-isoquinoline, leurs sels pharmaceutiquement acceptables, procédé de production associé et composition contenant les dérivés comme principe actif pour la prophylaxie et le traitement d'états pathologiques induits par l'hyperactivité de la kinase raf | |
WO2018021826A1 (fr) | Nouveau dérivé de pyrimidine-2,4-diamine et composition pharmaceutique pour la prévention ou le traitement du cancer contenant celui-ci comme ingrédient actif | |
WO2011122815A2 (fr) | Nouveaux dérivés de quinoxaline | |
WO2016006975A2 (fr) | Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation | |
WO2018056621A1 (fr) | Nouveau dérivé de pyrimidine imidazolyle, son procédé de préparation et une composition pharmaceutique le contenant en tant que principe actif pour prévenir ou traiter le cancer | |
WO2011049274A1 (fr) | Dérivés d'imidazole et compositions pour le traitement d'un mélanome | |
WO2017131425A1 (fr) | Nouveau dérivé d'imidazole présentant une activité inhibitrice de la jnk et son utilisation | |
WO2020013531A1 (fr) | Dérivé de n-(3-(imidazo[1,2-b]pyridazine-3-yléthynyl)-4-méthylphényl)-5-phényl-4,5-dihydro-1h-pyrazole-1-carboxamide, et composition pharmaceutique le contenant en tant que principe actif pour le traitement de maladies associées à une kinase | |
WO2018139883A1 (fr) | Dérivé de pyrimidine condensé à titre d'inhibiteur de kinase multi-cible | |
WO2021137665A1 (fr) | Composé dérivé de 1,2,3-triazole utilisé en tant qu'inhibiteur de hsp90, et son utilisation | |
WO2021040422A1 (fr) | Nouveau dérivé de pyrimido[4,5-d]pyrimidine-2-one ayant une activité inhibitrice de protéine kinase | |
WO2017164705A1 (fr) | Nouveau dérivé de pyridine, son procédé de préparation, et composition pharmaceutique pour prévenir ou traiter une maladie liée à fgfr contenant ledit dérivé comme principe actif | |
WO2021112626A1 (fr) | Nouveau dérivé d'indirubine et son utilisation | |
WO2018021762A1 (fr) | Nouveau composé, son procédé de préparation, et composition pharmaceutique le contenant | |
EP3166945A2 (fr) | Nouveaux dérivés triazolopyrimidinone ou triazolopyridinone et leur utilisation | |
WO2019098785A1 (fr) | Dérivé de 7-amino-1h-indole-5-carboxamide et utilisation correspondante | |
WO2022119090A1 (fr) | Dérivés de biphénylpyrrolidine et de biphényldihydroimidazole permettant d'inhiber l'activité du récepteur 5-ht7 de la sérotonine, et composition pharmaceutique le comprenant comme principe actif |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09814802 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09814802 Country of ref document: EP Kind code of ref document: A2 |